Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS

Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway

Published:2022-04 Issue:4 Volume:50 Page:030006052210933
ISSN:0300-0605
Container-title:Journal of International Medical Research
language:en
Short-container-title:J Int Med Res

Author:

Chen Di¹²³,Wei Xinyue¹²,Yang Ke¹²,Liu Xinyue¹²,Song Yujin¹²,Bai Futing¹²,Jiang Yi¹²,Guo Yuhang¹²,Jha Rajiv Kumar²^ORCID

Affiliation:

1. Institute of Basic Medical Sciences, Xi’an Medical University, Xi’an, Shaanxi Province, China

2. China-Nepal Friendship Medical Research Centre of Rajiv Kumar Jha, School of Clinical Medicine, Xi’an Medical University, Xi’an, Shaanxi Province, China

3. Xi’an Key Laboratory of Pathogenic Microorganism and Tumour Immunity, Xi’an Medical University, Xi’an, Shaanxi Province, China

Abstract

Objective To investigate the effects of piperlongumine (PL) and vitamin C (VC) on signal transducer and activator of transcription 3 (STAT3) signalling in gastric cancer cell lines. Methods In vivo tumour xenograft anticancer assays were undertaken to confirm the anticancer activity of PL. Cell viability, flow cytometry and Western blot assays were undertaken to evaluate the anticancer effects of PL, VC and combinations of PL and VC in AGS and KATO III cells. Results Both PL and VC induced apoptosis and inhibited cell proliferation in AGS and KATO III cells. These effects were dependent on reactive oxygen species (ROS). PL effectively suppressed STAT3 activation while VC caused abnormal activation of STAT3. The combination of PL and VC exhibited a stronger apoptotic effect compared with either agent alone. PL reversed the abnormal activation of STAT3 by VC, which could be a key to their synergistic effect. Conclusions PL combined with VC exhibited a stronger anticancer effect by regulating the ROS–STAT3 pathway, suggesting that this combination might be a potential adjuvant therapy for gastric cancer.

Publisher

SAGE Publications

Subject

Biochemistry (medical),Cell Biology,Biochemistry,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/03000605221093308

Reference39 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

2. Targeted and immunotherapy in the era of personalised gastric cancer treatment

3. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)

4. Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicity

5. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amide Alkaloids as Privileged Sources of Senomodulators for Therapeutic Purposes in Age-Related Diseases;Journal of Natural Products;2024-03-04

2. Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy;FEBS Open Bio;2023-05-20

3. Drug Repurposing in Gastric Cancer: Current Status and Future Perspectives;Hereditary Gastric and Breast Cancer Syndrome;2023